Gilead pays $40m to settle allegations that it delayed work on an improved HIV drug to maximise profits from an older drug.

Authors :: Dyer O
Source :: BMJ (Clinical research ed.) [BMJ] 2024 Jun 11; Vol. 385, pp. q1285. Date of Electronic Publication: 2024 Jun 11.
Publication Year :: 2024

Subjects :: Humans
Drug Industry economics
Drug Industry legislation & jurisprudence
HIV Infections drug therapy
HIV Infections economics
Anti-HIV Agents economics
Anti-HIV Agents therapeutic use

Full Text Access

Tools